Revenio Group Oyj - Managers' transactions

Revenio Group Corporation: Managers' transactions

 Revenio Group Corporation, Managers' transactions, May 31, 2017 at 15:30

 Revenio Group Corporation: Managers' transactions

 Person subject to the notification requirement

 Name:                    Hildén, Timo

 Position:                Chief Executive Officer


-------------------------------------------------------------------------------
 Initial Notification

 Reference number:        743700I27E0FWSXLKK04_20170524134544_2


-------------------------------------------------------------------------------
 Issuer

 Name:                    Revenio Group Oyj

 LEI:                     743700I27E0FWSXLKK04


-------------------------------------------------------------------------------
 Transaction details

 Transaction date:        2017-05-30

 Nature of the            Acceptance of a Stock Option
 transaction:

 Further details:

                          Linked to stock option programme



 Instrument:              Financial Instrument Linked to a Share or a Debt
                          Instrument

 ISIN:                    FI4000261037



 Volume:                  7500

 Unit price:



 Aggregated transactions

 Volume:                  7500

 Volume weighted average
 price:

For further information, please contact: Robin Pulkkinen, CFO, +358 50 5059932

Distribution:
Nasdaq Helsinki
www.revenio.fi

The Revenio Group in brief

Revenio is a Finnish, globally operating health technology corporation whose
worldwide success is based on a strongly patented intraocular pressure
measurement technology. The Revenio Group consists of Icare Finland Oy, Revenio
Research Oy and Oscare Medical Oy, in which Revenio holds a 53.5% interest. The
common denominators of Revenio's business operations include screening, follow-
up and the global need to make cost savings through preventive health care.
Revenio seeks vigorous growth in health technology. Revenio aims to develop even
more efficient and easily adopted methods for the early-stage detection of
diseases with significance for public health. The focus of Revenio's screening
technology is on the early detection of glaucoma, osteoporosis, skin cancer and
asthma, and the monitoring of these during the treatment process.

In 2016, Revenio Group's net sales totaled MEUR 23.4, with its operating profit
for continuing operations standing at 30.1%. Revenio Group Corporation is listed
on Nasdaq Helsinki.


[]